Presented by RGA
GLP‑1 therapies are emerging as a critical area of focus for both population health and insurance risk. In this roundtable, RGA’s biometric experts examine the latest research and early evidence, unpacking what these therapies could mean in an evolving and uncertain landscape.
Key takeaways: